Chronic fluoxetine reduces autonomic control of cardiac rhythms in rats with congestive heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 3, 2013, Pages

  Henze, Marcus ^a   Tiniakov, Ruslan ^a   Samarel, Allen ^a   Holmes, Earle ^a   Scrogin, Karie ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Heart rate variability; Selective serotonin reuptake inhibitor

Indexed keywords

CATECHOLAMINE; FLUOXETINE; ISOPRENALINE;

ANIMAL MODEL; ARTICLE; AUTONOMIC NERVE; BLOOD PRESSURE; CATECHOLAMINE BRAIN LEVEL; CONGESTIVE HEART FAILURE; HEART FUNCTION; HEART RATE VARIABILITY; HEART RHYTHM; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; RAT; VAGUS NERVE STIMULATION;

ANIMALS; ARRHYTHMIAS, CARDIAC; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CATECHOLAMINES; CORONARY VESSELS; DATA INTERPRETATION, STATISTICAL; ECHOCARDIOGRAPHY; ELECTRODES, IMPLANTED; FLUOXETINE; HEART; HEART FAILURE; HEART RATE; LIGATION; MALE; MYOCARDIAL CONTRACTION; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; SYMPATHETIC NERVOUS SYSTEM; TELEMETRY; VAGUS NERVE;

EID: 84873296083     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00763.2012     Document Type: Article

References (55)

1. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 213: 220-222, 1981.
2. Appel ML, Berger RD, Saul JP, Smith JM, Cohen RJ. Beat to beat variability in cardiovascular variables: noise or music? J Am Coll Cardiol 14: 1139-1148, 1989.
3. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and fj-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205-211, 1982.
4. Caccia S, Cappi M, Fracasso C, Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norflu-oxetine in the rat. Psychopharmacology (Berl) 100: 509-514, 1990.
5. Crestani CC, Tavares RF, Guimaraes FS, Correa FM, Joca SR, Resstel LB. Chronic fluoxetine treatment alters cardiovascular functions in unanesthetized rats. Eur J Pharmacol 670: 527-533, 2011.
6. Daly MD. Some reflex cardioinhibitory responses in the cat and their modulation by central inspiratory neuronal activity. J Physiol 439: 559-577, 1991.
7. Dawood T, Lambert EA, Barton DA, Laude D, Elghozi JL, Esler MD, Haikerwal D, Kaye DM, Hotchkin EJ, Lambert GW. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens Res 30: 285-293, 2007.
8. Dawood T, Lambert EA, Barton DA, Laude D, Elghozi JL, Esler MD, Haikerwal D, Kaye DM, Hotchkin EJ, Lambert GW. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens Res 30: 285-293, 2007.
9. Delville CL, McDougall G. A systematic review of depression in adults with heart failure: instruments and incidence. Issues Ment Health Nurs 29: 1002-1017, 2008.
10. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychophar-macology 29: 1321-1330, 2004.
11. Edgar VA, Cremaschi GA, Sterin-Borda L, Genaro AM. Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine. Brain Behav Immun 16: 333-350, 2002.
12. Freedland KE, Rich MW, Skala JA, Carney RM, Davila-Roman VG, Jaffe AS. Prevalence of depression in hospitalized patients with congestive heart failure. Psychosom Med 65: 119-128, 2003.
13. Glassman AH, Bigger JT, Gaffney M, van Zyl LT. Heart rate variability in acute coronary syndrome patients with major depression: influence of sertraline and mood improvement. Arch Gen Psychiatry 64: 1025-1031, 2007.
14. Guzzetti S, Rovere MT LA, Pinna GD, Maestri R, Borroni E, Porta A, Mortara A, Malliani A. Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure. Eur Heart J 26: 357-362, 2005.
15. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabo-lizers of debrisoquin. Clin Pharmacol Ther 60: 512-521, 1996.
16. Henje BE, Olsson EM, Serlachius E, Ericson M, Ingvar M. Heart rate variability (HRV) in adolescent females with anxiety disorders and major depressive disorder. Acta Paediatr 99: 604-611, 2010.
17. Henze M, Hart D, Samarel A, Barakat J, Eckert L, Scrogin K. Persistent alterations in heart rate variability, baroreflex sensitivity, and anxiety-like behaviors during development of heart failure in the rat. Am J Physiol Heart Circ Physiol 295: H29-H38, 2008.
18. Jiang W, Krishnan R, Kuchibhatla M, Cuffe MS, Martsberger C, Arias RM, O'Connor CM. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol 107: 545-551, 2011.
19. Kawachi I, Colditz GA, Ascherio A, Rimm EB, Giovannucci E, Stampfer MJ, Willett WC. Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation 89: 1992-1997, 1994.
20. Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation 90: 2225-2229, 1994.
21. Kemp AH, Quintana DS, Felmingham KL, Matthews S, Jelinek HF. Depression, comorbid anxiety disorders, and heart rate variability in physically healthy, unmedicated patients: implications for cardiovascular risk. PLos One 7: e30777, 2012.
22. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry 67: 1067-1074, 2010.
23. Khaykin Y, Dorian P, Baker B, Shapiro C, Sandor P, Mironov D, Irvine J, Newman D. Autonomic correlates of antidepressant treatment using heart-rate variability analysis. Can J Psychiatry 43: 183-186, 1998.
24. Kiviniemi AM, Tulppo MP, Wichterle D, Hautala AJ, Tiinanen S, Seppanen T, Makikallio TH, Huikuri HV. Novel spectral indexes of heart rate variability as predictors of sudden and non-sudden cardiac death after an acute myocardial infarction. Ann Med 39: 54-62, 2007.
25. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myo-cardial infarction. Am J Cardiol 59: 256-262, 1987.
26. Koran LM, Cain JW, Dominguez RA, Rush AJ, Thiemann S. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry 153: 1450-1454, 1996.
27. Lederbogen F, Gernoth C, Weber B, Colla M, Kniest A, Heuser I, Deuschle M. Antidepressive treatment with amitriptyline and paroxetine: comparable effects on heart rate variability. J Clin Psychopharmacol 21: 238-239, 2001.
28. Leftheriotis D, Flevari P, Ikonomidis I, Douzenis A, Liapis C, Para-skevaidis I, Iliodromitis E, Lykouras L, Kremastinos DT. The role of the selective serotonin re-uptake inhibitor sertraline in nondepressive patients with chronic ischemic heart failure: a preliminary study. Pacing Clin Electrophysiol 33: 1217-1223, 2010.
29. Licht CM, de Geus EJ, van Dyck R, Penninx BW. Association between anxiety disorders and heart rate variability in The Netherlands Study of Depression and Anxiety (NESDA). Psychosom Med 71: 508-518, 2009.
30. Licht CM, de Geus EJ, van Dyck R, Penninx BW. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry 68: 861-868, 2010.
31. Licht CM, de Geus EJ, van Dyck R, Penninx BW. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry 68: 861-868, 2010.
32. Licht CM, de Geus EJ, Zitman FG, Hoogendijk WJ, van Dyck R, Penninx BW. Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA). Arch Gen Psychiatry 65: 1358-1367, 2008.
33. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 84: 482-492, 1991.
34. McFarlane A, Kamath MV, Fallen EL, Malcolm V, Cherian F, Norman G. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 142: 617-623, 2001.
35. Motte S, Mathieu M, Brimioulle S, Pensis A, Ray L, Ketelslegers JM, Montano N, Naeije R, van De BP, Entee KM. Respiratory-related heart rate variability in progressive experimental heart failure. Am J Physiol Heart Circ Physiol 289: H1729-H1735, 2005.
36. Nahshoni E, Aravot D, Aizenberg D, Sigler M, Zalsman G, Strasberg B, Imbar S, Adler E, Weizman A. Heart rate variability in patients with major depression. Psychosomatics 45: 129-134, 2004.
37. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50: 345-350, 2001.
38. Perlini S, Giangregorio F, Coco M, Radaelli A, Solda PL, Bernardi L, Ferrari AU. Autonomic and ventilatory components of heart rate and blood pressure variability in freely behaving rats. Am J Physiol Heart Circ Physiol 269: H1729-H1734, 1995.
39. Qu Y, Aluisio L, Lord B, Boggs J, Hoey K, Mazur C, Lovenberg T. Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex. Pharmacol Biochem Behav 92: 469-473, 2009.
40. Rissanen A, Naukkarinen H, Virkkunen M, Rawlings RR, Linnoila M. Fluoxetine normalizes increased cardiac vagal tone in bulimia nervosa. J Clin Psychopharmacol 18: 26-32, 1998.
41. Schwartz PJ, De Ferrari GM. Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev 16: 101-107, 2011.
42. Somberg TC, Arora RR. Depression and heart disease: therapeutic implications. Cardiology 111: 75-81, 2008.
43. Stanton T, Bolden-Watson C, Cusack B, Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol 45: 2352-2354, 1993.
44. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93: 1043-1065, 1996.
45. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62: 792-798, 2005.
46. Teerlink JR, Clozel JP. Hemodynamic variability and circadian rhythm in rats with heart failure: role of locomotor activity. Am J Physiol Heart Circ Physiol 264: H2111-H2118, 1993.
47. Testa G, Cacciatore F, Galizia G, Della-Morte D, Mazzella F, Gar-giulo G, Langellotto A, Raucci C, Ferrara N, Rengo F, Abete P. Depressive symptoms predict mortality in elderly subjects with chronic heart failure. Eur J Clin Invest 41: 1310-1317, 2011.
48. Tousoulis D, Antoniades C, Drolias A, Stefanadi E, Marinou K, Vasiliadou C, Tsioufis C, Toutouzas K, Latsios G, Stefanadis C. Selective serotonin reuptake inhibitors modify the effect of fj-blockers on long-term survival of patients with end-stage heart failure and major depression. J Card Fail 14: 456-464, 2008.
49. van Zyl LT, Hasegawa T, Nagata K. Effects of antidepressant treatment on heart rate variability in major depression: a quantitative review. Biopsychosoc Med 2: 12, 2008.
50. Verkerk AO, Wilders R, Coronel R, Ravesloot JH, Verheijck EE. Ionic remodeling of sinoatrial node cells by heart failure. Circulation 108: 760-766, 2003.
51. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 8: 337-344, 1993.
52. Wong DT, Fuller RW, Robertson DW. Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm Nord 2: 171-180, 1990.
53. Wong SH, Dellafera SS, Fernandes R, Kranzler H. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. J Chromatogr 499: 601-608, 1990.
54. Wyman L, Crum RM, Celentano D. Depressed mood and cause-specific mortality: a 40-year general community assessment. Ann Epidemiol 22: 638-643, 2012.
55. Wyman L, Crum RM, Celentano D. Depressed mood and cause-specific mortality: a 40-year general community assessment. Ann Epidemiol 22: 638-643, 2012.